From toxicity assessment to adaptive safety care: implementing comprehensive fast-track safety evaluation for anticancer drug development

The conventional drug development pathway in oncology, spanning 10-15 years, has long been slow, costly, and complex, often marked by late-stage failures due to efficacy or safety concerns.

We aimed to develop this position paper, based on a literature review and by sharing experience, skills, and works of the different co-authors, in order to propose a new approach to the clinical trials' process.